報價延遲最少15分鐘:2024/04/26 01:07 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.6 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-21.60/-1.16
|
|
企業價值
14.75M
|
| 資產負債 |
|
每股賬面淨值
21.64
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
42.81M
|
|
每股收益
26.85
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/04/26 01:07 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States. |